Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
42
2
2
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 42 trials
100.0%
+13.5% vs industry average
29%
12 trials in Phase 3/4
0%
0 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (42)
The Surveillance Clinical Study of Rickettsiosis
Role: lead
Clinical Study of the Safety and Pharmacokinetics of the Drug Fluorothiazinone, a Concentrate for Solution Preparation for Infusion.
Role: lead
"Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Drug B10-FC After Single Administration to Adult Patients".
Role: lead
Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV
Role: lead
Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa
Role: lead
An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"
Role: lead
Study of the Drug B11-FC (Botulism Treatment)
Role: lead
An Open-label Study of the Safety and Pharmacokinetics of the TGKP
Role: lead
Study of the Vector Vaccine GamCovidVac-M (Altered Antigenic Composition)
Role: lead
Study of the Vector Vaccine GamCovidVac for the Prevention of COVID-19 With Altered Antigenic Profile With Participation of Adult Volunteers
Role: lead
Study of "Sputnik Lite" for the Prevention of COVID-19 With Altered Antigenic Composition.
Role: lead
Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19
Role: collaborator
Study of Monoclonal Antibodies for Early Etiotropic Therapy for Coronavirus Infection Caused by the SARS-CoV-2 Virus
Role: lead
Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
Role: lead
HIV A6 Genome In ART Unsuccessful Patients On DOR
Role: lead
Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray
Role: lead
Study of Gam-COVID-Vac in Adolescents
Role: lead
Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection
Role: collaborator
Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light
Role: lead
An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease
Role: lead